filmov
tv
Extended Aromatase Inhibitor Risk/Benefit

Показать описание
Hope S. Rugo, MD, and Ruth O’Regan, MD, discuss the toxicities, risk/benefit profile, and side effects of extended aromatase inhibitors in breast cancer.
Extended Aromatase Inhibitor Risk/Benefit
Managing the Side Effects of Aromatase Inhibitors and Tamoxifen
Aromatase Inhibitors Risk To Benefit Ratio
Aromatase Inhibitors: Risks & Benefits For Breast Cancer Patients
Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer
5 years of additional AI no better than 2 in HR+ breast cancer
Not All Women Who Are Clinically High-Risk Benefit from Extended Endocrine Therapy
Two years of extended anastrazole therapy as effective as five
Should I Shut Down My Ovaries for Breast Cancer?
Benefits of Aromatase Inhibitors After 5 Years of Tamoxifen
Dr. Graff on Extended Adjuvant Therapy in Early-Stage HR+ Breast Cancer
Using Aromatase Inhibitors Longer Than 5 Years
ASCO Breast Cancer Update | Jane Meisel, MD | 2022 Review and Renew Sedona
Virtual Pink House: Tamoxifen & Aromatase Inhibitors in ER+ Breast Cancer
Risk of Early Versus Late Recurrence
An Overview of the MA17R Trial in Breast Cancer
Find Your Finish to Anti-Estrogen Therapy: It Starts with the Breast Cancer Index Test
Breast Cancer Risk-reducing Medications
Should I Take an Aromatase Inhibitor? (5 Things Breast Cancer Survivors Are Not Told)
Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast Cancer
Do You Want to Stop Hormonal Therapy for HR+ Breast Cancer?
Updates in Extended Endocrine Therapy for HR+ Breast Cancer | ASCO21 & National Practice Guideli...
Tamoxifen reduces breast cancer risk
Compass Talks: Lucy Langer, MD --- Extended adjuvant therapy in ER and breast cancer.
Комментарии